Biotech News

Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain

Tonix Pharmaceuticals (TNXP)Tonix Pharmaceuticals2026-03-26 11:00 ESTClinical readout

TNXP (TNXP) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is tnxp.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

TNXPTonix Pharmaceuticals2026-06-29 11:25 EST

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

TNXPTonix Pharmaceuticals2026-04-29 11:00 EST

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University

OGENOragenics2026-05-05 12:30 EST

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

OGENOragenics2026-04-13 12:30 EST

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

ALZNAlzamend Neuro2026-04-07 12:00 EST

Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital

NERVMinerva Neuroscience2026-03-31 20:05 EST

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

TSHATaysha Gene Therapies2026-06-22 12:00 EST

Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome

PRAXPraxis Precision Medicines2026-04-13 12:00 EST

Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026

ALKSAlkermes plc2026-04-01 11:00 EST

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

TEVATeva Pharmaceutical Industries2026-06-18 20:57 EST

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

View all latest news

Tonix Pharmaceuticals

Tonix Pharmaceuticals is a neuroscience and infectious-disease company with a wide-ranging pipeline and a long-running development story. Its business has included central nervous system, pain, and vaccine-related programs.

Recent company news

TNXPTonix Pharmaceuticals2026-07-27 11:00 EST

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

TNXPTonix Pharmaceuticals2026-07-15 13:05 EST

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

TNXPTonix Pharmaceuticals2026-07-13 11:00 EST

Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®

TNXPTonix Pharmaceuticals2026-06-29 11:25 EST

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

TNXPTonix Pharmaceuticals2026-06-11 11:00 EST

Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026

Stock data

Close: 10.37 USD
Market cap: 186.83M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States